-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodology: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients
Kevin D Hill, Jennifer S Li, Christoph P Hornik
Editorial: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Richard J Stephens
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Is there a future for CETP-inhibitor therapy?
Jennifer G Robinson
Editorial: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation
-
Strategies to treat sepsis: old and new
Steven P LaRosa, Steven M Opal
Therapeutic Prospective: Clinical Investigation